Trial Profile
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety of BONVIVA(Ibandronate) Injection Administered in Korean Patients According to the Prescribing Information.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions
- Acronyms BONINJPMS
- Sponsors GlaxoSmithKline; GSK
- 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Nov 2012 Planned End Date changed from 1 Nov 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 23 Jun 2011 New trial record